Effects of carvedilol on M2 receptors and cholinesterase-positive nerves in adriamycin-induced rat failing heart

Auton Neurosci. 2006 Dec 30;130(1-2):6-16. doi: 10.1016/j.autneu.2006.04.005. Epub 2006 Jun 23.

Abstract

Heart failure is correlated with attenuation of parasympathetic nervous function and enhanced sympathetic activity. Carvedilol, a third-generation beta-blocker, may improve the prognosis of heart failure better than selective beta(1)-blockers. Not all of its effects, however, can be explained by direct actions on the sympathetic nervous system. This study was therefore performed to investigate the possible alterations of muscarinic cholinergic (M)(2) receptors and cholinesterase-positive nerves in different regions of the adriamycin-induced failing rat heart, and the potential effects of carvedilol on these M(2) receptors and cholinesterase-positive nerves. Karnovsky-Roots histochemical staining combined with point counting methods, and immunochemical streptavidin-biotin complex staining and image analysis were used to test the distribution of cholinesterase-positive nerves and the expression of M(2) receptors, respectively. Our results show that the cholinesterase-positive nerve system was downregulated in the adriamycin-induced failing heart group, while the density of M(2) receptors was increased in the carvedilol 3- and 10-mg/kg body weight groups, especially in the endocardial tissues of the left-ventricular free wall. It is concluded that upregulation of M(2) receptors may be one of the potential mechanisms by which carvedilol exert its action on heart failure.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic alpha-Antagonists / pharmacology*
  • Adrenergic alpha-Antagonists / therapeutic use
  • Adrenergic beta-Antagonists / pharmacology*
  • Adrenergic beta-Antagonists / therapeutic use
  • Animals
  • Carbazoles / pharmacology*
  • Carbazoles / therapeutic use
  • Carvedilol
  • Cholinesterases / analysis*
  • Down-Regulation / drug effects
  • Doxorubicin / toxicity
  • Endocardium / drug effects
  • Endocardium / innervation
  • Heart Atria / chemistry
  • Heart Atria / innervation
  • Heart Atria / pathology
  • Heart Conduction System / drug effects*
  • Heart Conduction System / ultrastructure
  • Heart Failure / chemically induced
  • Heart Failure / drug therapy*
  • Heart Failure / physiopathology
  • Heart Ventricles / chemistry
  • Heart Ventricles / innervation
  • Heart Ventricles / pathology
  • Male
  • Nerve Fibers / drug effects*
  • Nerve Fibers / enzymology
  • Nerve Tissue Proteins / analysis*
  • Parasympathetic Nervous System / drug effects*
  • Parasympathetic Nervous System / physiopathology
  • Propanolamines / pharmacology*
  • Propanolamines / therapeutic use
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Muscarinic M2 / biosynthesis
  • Receptor, Muscarinic M2 / drug effects*
  • Ventricular Dysfunction, Left / drug therapy
  • Ventricular Dysfunction, Left / physiopathology

Substances

  • Adrenergic alpha-Antagonists
  • Adrenergic beta-Antagonists
  • Carbazoles
  • Nerve Tissue Proteins
  • Propanolamines
  • Receptor, Muscarinic M2
  • Carvedilol
  • Doxorubicin
  • Cholinesterases